Table 2. Mutations detected in the baseline drug resistance testing (bDRT); global results and results by patient.

Baseline characteristics			Patients (N = 135)
Major mutations in Baseline drug resistance testing (bDRT), n (%)	17 (12.6)	INSTIs	1 (0.7)	G163K
		PIs	1 (0.7)	V82C
		NNRTIs	12 (8.9)	E138A(3), K103N(6), V106I(3), V108Vi, E138EG, G190A
		NRTIs	5 (3.7)	M184V (2), M14L, E44D, T215D, T215C, L210W, T215S
Results by patient
Participant	Major mutations in bDRT		Antiretroviral family affected
1	G163K		INSTIs
2	E138EG		NNRTIs
3	M14L, E44D, T215D		NRTIs
4	K103N		NNRTIs
5	K103N		NNRTIs
6	L210W, T215S		NRTIs
7	E138A		NNRTIs
8	V106I		NNRTIs
9	V106I, G190A		NNRTIs
10	K103N, E138A		NNRTIs
11	V106I		NNRTIs
12	K103N, M184V		NNRTIs and NRTIs
13	M184V		NRTIs
14	V82C		PIs
15	K103N, V108Vi, T215C		NNRTIs and NRTIs
16	E138A		NNRTIs
17	K103N		NNRTIs

bDRT: Baseline drug resistance testing; INSTIs = integrase strand transfer inhibitors; PIs = protease inhibitors; NNRTIs = non-nucleoside reverse transcriptase inhibitors; NRTIs = nucleoside reverse transcriptase inhibitors.